MAF has received grant/research support from Abbott Laboratories, American Foundation for Suicide Prevention, GlaxoSmithKline, National Institute of Mental Health, Pfizer Inc., Solvay Pharmaceuticals, Stanley Medical Research Institute; consultant for Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Cephalon, Elan Pharmaceuticals, Eli Lilly & Co., GlaxoSmithKline, Janssen-Cilag, Johnson & Johnson PRD, Novartis Pharmaceuticals, Ortho McNeil, Otsuka Pharmaceuticals, Pfizer Inc., UCB Pharma; and serves on the speakers bureau for Abbott Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly & Co., GlaxoSmithKline, Janssen-Cilag, Novartis Pharmaceuticals, Ortho McNeil, Otsuka Pharmaceuticals; financial interest/stock ownership – none. LLA has received grant/research support from Abbott Laboratories; consultant/scientific advisory boards for Abbott Laboratories, Bristol-Meyers Squibb, Eli Lilly & Co., Forest Laboratories, Janssen, AstraZeneca; advisory board for Pfizer; has received honoraria from Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly & Co., Forest Laboratories, Janssen; and serves on the speakers bureau for Abbott Laboratories. JWM and MJG have no reported conflicts of interest.
Patterns of alcohol consumption in bipolar patients comorbid for alcohol abuse or dependence
Article first published online: 15 JUL 2005
Volume 7, Issue 4, pages 377–381, August 2005
How to Cite
McKowen, J. W., Frye, M. A., Altshuler, L. L. and Gitlin, M. J. (2005), Patterns of alcohol consumption in bipolar patients comorbid for alcohol abuse or dependence. Bipolar Disorders, 7: 377–381. doi: 10.1111/j.1399-5618.2005.00208.x
- Issue published online: 15 JUL 2005
- Article first published online: 15 JUL 2005
- Received 18 June 2004, revised and accepted for publication 11 March 2005
Objectives: Despite a high prevalence rate, patients with bipolar disorder and active alcohol use are routinely excluded from controlled clinical trials leaving clinicians with little evidence-based medicine to guide treatment. This report evaluates preliminary data of alcohol consumption patterns utilizing the Alcohol Timeline Followback (TLFB) method in actively drinking patients with bipolar disorder.
Methods: A sample of 30 patients underwent a Structured Diagnostic Interview for DSM-IV (SCID-IV) as well as completing various measures of alcohol use and associated morbidity.
Results: In the month prior to study entry, the TLFB reported 18.4/30 ± 9.12 drinking days, 9.9 ± 4.73 drinks per drinking day and 169.4 ± 101.71 total standard drinks for this study group. There was a significant difference in the number of drinks per drinking day between those diagnosed with rapid cycling than non-rapid cycling bipolar disorder and those with a new diagnosis versus established diagnosis of bipolar disorder.
Discussion: This study highlights heavy alcohol use in patients with bipolar disorder and alcohol comorbidity. The TLFB method provides ‘real world’ quantification of use. Further studies are encouraged to elucidate implications of heavy drinking patterns as found in our rapid cycling and newly diagnosed cohorts.